Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors

A Phase 1 Study Of CP- 870,893 In Combination With Paclitaxel And Carboplatin In Patients With Metastatic Solid Tumors

This is a dose-finding study; therefore, there is no hypothesis testing

Inclusion Criteria:

• Patients with metastatic solid tumors, for whom carboplatin and paclitaxel are appropriate;
• Patients >18 years of age;
• Good performance status;
• Adequate bone marrow and organ function

Exclusion Criteria:

• Previous treatment with any other compound that targets CD40
• Current or planned concurrent treatment with any anticancer agent;
• Patients who have received bone marrow transplant;
• History of autoimmune disorder
• History (within the previous year) of heart failure or heart attack
• Cancer-associated coagulation disorders